151 related articles for article (PubMed ID: 27610034)
1. Histone deacetylase inhibitor, CG200745, attenuates cardiac hypertrophy and fibrosis in DOCA-induced hypertensive rats.
Lee E; Song MJ; Lee HA; Kang SH; Kim M; Yang EK; Lee do Y; Ro S; Cho JM; Kim I
Korean J Physiol Pharmacol; 2016 Sep; 20(5):477-85. PubMed ID: 27610034
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of C/EBPβ and TSC2 by an HDAC inhibitor CG200745 protects heart from DOCA-induced hypertrophy.
Lee E; Lee HA; Kim M; Do GY; Cho HM; Kim GJ; Jung H; Song JH; Cho JM; Kim I
Clin Exp Pharmacol Physiol; 2019 Mar; 46(3):226-236. PubMed ID: 30099761
[TBL] [Abstract][Full Text] [Related]
3. Renoprotective Effect of the Histone Deacetylase Inhibitor CG200745 in DOCA-Salt Hypertensive Rats.
Bae EH; Kim IJ; Song JH; Choi HS; Kim CS; Eom GH; Kim I; Cha H; Cho JM; Ma SK; Kim SW
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30691015
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitor CG200745 ameliorates high-fat diet-induced hypertension via inhibition of angiotensin II production.
Yoon GE; Jung JK; Lee YH; Jang BC; In Kim J
Naunyn Schmiedebergs Arch Pharmacol; 2020 Mar; 393(3):491-500. PubMed ID: 31655853
[TBL] [Abstract][Full Text] [Related]
5. HDAC inhibition suppresses cardiac hypertrophy and fibrosis in DOCA-salt hypertensive rats via regulation of HDAC6/HDAC8 enzyme activity.
Kee HJ; Bae EH; Park S; Lee KE; Suh SH; Kim SW; Jeong MH
Kidney Blood Press Res; 2013; 37(4-5):229-39. PubMed ID: 23868068
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitor, CG200745 attenuates renal fibrosis in obstructive kidney disease.
Choi HS; Song JH; Kim IJ; Joo SY; Eom GH; Kim I; Cha H; Cho JM; Ma SK; Kim SW; Bae EH
Sci Rep; 2018 Aug; 8(1):11546. PubMed ID: 30068917
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibition attenuates cardiac hypertrophy and fibrosis through acetylation of mineralocorticoid receptor in spontaneously hypertensive rats.
Kang SH; Seok YM; Song MJ; Lee HA; Kurz T; Kim I
Mol Pharmacol; 2015 May; 87(5):782-91. PubMed ID: 25667225
[TBL] [Abstract][Full Text] [Related]
8. Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats.
Iyer A; Fenning A; Lim J; Le GT; Reid RC; Halili MA; Fairlie DP; Brown L
Br J Pharmacol; 2010 Apr; 159(7):1408-17. PubMed ID: 20180942
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitor, mocetinostat, regulates cardiac remodelling and renin-angiotensin system activity in rats with transverse aortic constriction-induced pressure overload cardiac hypertrophy.
Kim GJ; Jung H; Lee E; Chung SW
Rev Cardiovasc Med; 2021 Sep; 22(3):1037-1045. PubMed ID: 34565105
[TBL] [Abstract][Full Text] [Related]
10. Genetic ablation and pharmacological inhibition of immunosubunit β5i attenuates cardiac remodeling in deoxycorticosterone-acetate (DOCA)-salt hypertensive mice.
Cao HJ; Fang J; Zhang YL; Zou LX; Han X; Yang J; Yan X; Li PB; Wang HX; Guo SB; Li HH
J Mol Cell Cardiol; 2019 Dec; 137():34-45. PubMed ID: 31629736
[TBL] [Abstract][Full Text] [Related]
11. Knockout of immunoproteasome subunit β2i ameliorates cardiac fibrosis and inflammation in DOCA/Salt hypertensive mice.
Yan W; Bi HL; Liu LX; Li NN; Liu Y; Du J; Wang HX; Li HH
Biochem Biophys Res Commun; 2017 Aug; 490(2):84-90. PubMed ID: 28478040
[TBL] [Abstract][Full Text] [Related]
12. Cardiac and vascular responses in deoxycorticosterone acetate-salt hypertensive rats.
Brown L; Ooi SY; Lau K; Sernia C
Clin Exp Pharmacol Physiol; 2000 Apr; 27(4):263-9. PubMed ID: 10779123
[TBL] [Abstract][Full Text] [Related]
13. Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system.
Brown L; Duce B; Miric G; Sernia C
J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S143-8. PubMed ID: 9892155
[TBL] [Abstract][Full Text] [Related]
14. Chronic angiotensin blockade with candesartan cilexetil in DOCA/salt hypertensive rats reduces cardiac hypertrophy and coronary resistance without affecting blood pressure.
Fujita H; Takeda K; Miki S; Morimoto S; Kawa T; Uchida A; Itoh H; Nakata T; Sasaki S; Nakagawa M
Hypertens Res; 1997 Dec; 20(4):263-7. PubMed ID: 9453261
[TBL] [Abstract][Full Text] [Related]
15. Effect of chronic treatment with two different ET(A) selective endothelin receptor antagonists on blood pressure and small artery structure of deoxycorticosterone acetate (DOCA)-salt hypertensive rats.
Li JS; Turgeon A; Schiffrin EL
Am J Hypertens; 1998 May; 11(5):554-62. PubMed ID: 9633791
[TBL] [Abstract][Full Text] [Related]
16. Lifetime overproduction of circulating Angiotensin-(1-7) attenuates deoxycorticosterone acetate-salt hypertension-induced cardiac dysfunction and remodeling.
Santiago NM; Guimarães PS; Sirvente RA; Oliveira LA; Irigoyen MC; Santos RA; Campagnole-Santos MJ
Hypertension; 2010 Apr; 55(4):889-96. PubMed ID: 20212262
[TBL] [Abstract][Full Text] [Related]
17. Tranilast attenuates myocardial fibrosis in association with suppression of monocyte/macrophage infiltration in DOCA/salt hypertensive rats.
Kagitani S; Ueno H; Hirade S; Takahashi T; Takata M; Inoue H
J Hypertens; 2004 May; 22(5):1007-15. PubMed ID: 15097242
[TBL] [Abstract][Full Text] [Related]
18. L-carnitine attenuates cardiac remodelling rather than vascular remodelling in deoxycorticosterone acetate-salt hypertensive rats.
O'Brien D; Chunduri P; Iyer A; Brown L
Basic Clin Pharmacol Toxicol; 2010 Apr; 106(4):296-301. PubMed ID: 20041879
[TBL] [Abstract][Full Text] [Related]
19. Enhanced expression of the endothelin-1 gene in blood vessels of DOCA-salt hypertensive rats: correlation with vascular structure.
Schiffrin EL; Larivière R; Li JS; Sventek P
J Vasc Res; 1996; 33(3):235-48. PubMed ID: 8924521
[TBL] [Abstract][Full Text] [Related]
20. Myocardial fibrosis in DOCA-salt hypertensive rats: effect of endothelin ET(A) receptor antagonism.
Ammarguellat F; Larouche I; Schiffrin EL
Circulation; 2001 Jan; 103(2):319-24. PubMed ID: 11208696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
